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Purpose: Prostate-specific membrane antigen (PSMA)-targeted positron emission 
tomography (PET) imaging has become commonly utilized in patients with prostate 
cancer (PCa). The PSMA reporting and data system version 1.0 (PSMA-RADS version 
1.0) categorizes lesions on the basis of the likelihood of PCa involvement, with PSMA-
RADS-3A (soft tissue) and PSMA-RADS-3B (bone) lesions being indeterminate for the 
presence of disease. We retrospectively reviewed the imaging follow-up of such lesions 
to determine the rate at which they underwent changes suggestive of underlying PCa. 
Methods: PET/CT imaging with 18F-DCFPyL was carried out in 110 patients with PCa 
and lesions were categorized according to PSMA-RADS Version 1.0. 56/110 (50.9%) 
patients were determined to have indeterminate PSMA-RADS-3A or PSMA-RADS-3B 
lesions and 22/56 (39.3%) patients had adequate follow-up to be included in the 
analysis. The maximum standardized uptake values (SUVmax) of the lesions were 
obtained and the ratios of SUVmax of the lesions to SUVmean of blood pool (SUVmax-
lesion/SUVmean-bloodpool) were calculated. Pre-determined criteria were used to evaluate the 
PSMA-RADS-3A and PSMA-RADS-3B lesions on follow-up imaging to determine if they 
demonstrated evidence of underlying malignancy. 
Results: A total of 46 lesions in 22 patients were considered indeterminate for PCa (i.e. 
PSMA-RADS-3A (32 lesions) or PSMA-RADS-3B (14 lesions)) and were evaluable on 
follow-up imaging. 27/46 (58.7%) lesions demonstrated changes on follow-up imaging 
consistent with the presence of underlying PCa at baseline. These lesions included 
24/32 (75.0%) PSMA-RADS-3A lesions and 3/14 (21.4%) lesions categorized as PSMA-
RADS-3B. The ranges of SUVmax and SUVmax-lesion/SUVmean-bloodpool overlapped between 
those lesions demonstrating changes consistent with malignancy on follow-up imaging 
and those lesions that remained unchanged on follow-up. 
Conclusion: PSMA-RADS-3A and PSMA-RADS-3B lesions are truly indeterminate in 
that proportions of findings in both categories demonstrate evidence of malignancy on 
follow-up imaging. Overall, PSMA-RADS-3A lesions are more likely than PSMA-RADS-
3B lesions to represent sites of PCa and this information should be taken into when 
guiding patient therapy.  
 








In 2018, prostate cancer (PCa) is estimated to be the most commonly diagnosed 
non-cutaneous malignancy as well as the second most common cause of cancer death 
in United States men (1).  Despite how common PCa is, imaging of this malignancy has 
long been challenging, particularly in patients with recurrent or metastatic disease (2). 
Although conventional imaging can often appropriately stage patients with very 
advanced disease, it has taken the advent of very sensitive molecular imaging agents to 
be able to reliably identify small volume disease that may be 
oligorecurrent/oligometastatic (3). Such disease may be amenable to metastasis-
directed therapy such as salvage lymphadenectomy or stereotactic body radiation 
therapy (SBRT) (4,5). Those interventions may allow a subset of patients to avoid 
systemic therapy, and in some cases patients may have prolonged progression-free 
survival (6). 
Among the molecular imaging agents for PCa, positron emission tomography 
(PET)-based radiotracers that target prostate-specific membrane antigen (PSMA) have 
shown both exceptional sensitivity and specificity (7,8). While the improved sensitivity of 
PSMA-targeted agents relative to conventional imaging has been well-established 
(2,7,9), that superior sensitivity appears to be true even when comparing PSMA-
targeted agents to older classes of PCa radiotracers (10,11). This has led to the 
extensive study of PSMA-targeted compounds in PCa biochemical recurrence (12,13), 
partially in the hope that detecting sites of recurrent PCa at low serum prostate specific 
antigen (PSA) levels may provide new options for metastasis-directed therapy for 
carefully selected patients. Indeed, as the number of publications on PSMA-targeted 
PET has increased, there has been a parallel increase in the number of papers on 
therapeutic options for oligometastatic PCa (3). 
With the implication that findings on PSMA-targeted PET will be used to guide 
therapy, having a standardized framework that demarcates individual lesions and 
incorporates information about the imaging specialist’s confidence that a lesion 
represents PCa is valuable. One such system that has been proposed is the PSMA 
reporting and data system version 1.0 (PSMA-RADS version 1.0) (14,15). PSMA-RADS 
is predicated on a 5-point scale with PSMA-RADS-3 indicating an indeterminate lesion. 
PSMA-RADS-3 can indicate findings, with or without radiotracer uptake, that are 
unlikely to represent PCa (PSMA-RADS-3C and PSMA-RADS-3D, respectively) 
(16,17). However, in most cases, indeterminate lesions are those findings that would be 
typical for PCa such as lymph node (PSMA-RADS-3A) or bone lesions (PSMA-RADS-
3B) and that have low levels of uptake and lack a correlative anatomic finding. In this 
study, we have longitudinally followed a series of PSMA-RADS-3A and PSMA-RADS-3B 
lesions to determine how frequently such findings definitively manifest as sites of cancer 
involvement.  
 
MATERIALS AND METHODS 
Patient Population 
110 consecutive patients with a history of pathologically diagnosed PCa who had 
undergone an 18F-DCFPyL PET/CT scan on a prospective research protocol 
(ClinicalTrials.gov NCT02825875) were included in this study. Patients were imaged 
under the auspices of a United States Food and Drug Administration Investigational 
New Drug Application (IND 121064). This study was approved by our hospital’s 
Institutional Review Board. All patients signed written, informed consent. Clinical and 
demographic information including ages, prostate-specific antigen levels, and PCa 
treatment history were collected. 
 
PET/CT imaging 
The radiosynthesis of 18F-DCFPyL was carried out as has been previously 
described (18). Images were acquired in a manner consistent with the methods 
described by Rowe and colleagues (19). In brief, all patients were asked to refrain from 
eating or drinking for at least 4 hours prior to the intravenous injection of approximately 
333 MBq (9 mCi) of 18F-DCFPyL. One hour following the injection, a whole-body 
PET/CT acquisition was performed (from the mid-thighs through the vertex of the skull) 
on either a 128-slice Biograph mCT scanner (Siemens, Erlangen, Germany) or a 64-
slice Discovery RX scanner (General Electric, Waukesha, Wisconsin, USA). For the 
acquisitions, the scanners were in 3D emission mode with attenuation correction 
provided by CT. 
 
Image Analysis 
18F-DCFPyL PET/CT scans were centrally reviewed by two experienced readers 
(YY and SPR) and lesions were categorized according to PSMA-RADS Version 1.0 
(14). The reviewers reached a consensus on all lesions included in the analysis. As had 
previously been set forth in the original PSMA-RADS manuscript (14), the central 
reviewers considered PSMA-RADS-3A lesions to be those lymph nodes or soft tissue 
findings that were in a typical pattern of distribution for PCa (e.g. pelvis and 
retroperitoneum, as well as mediastinum and left supraclavicular space in patients with 
more advanced disease (20)). PSMA-RADS-3B lesions could generally be described as 
sites of low level uptake in the bone without an appreciable anatomic correlate or with 
punctate sclerosis or other findings on corresponding CT that did not definitively 
suggest the presence of metastatic disease. 
For the patients with lesions categorized with PSMA-RADS-3A and/or PSMA-
RADS-3B, longitudinal follow-up imaging data were sought. Patients were included in 
further analysis if follow-up imaging at least three months after the baseline 18F-DCFPyL 
PET/CT was available in our institution’s Picture Archiving and Communications 
System. No specific limitations were set on the type of follow-up imaging that could be 
utilized, and imaging included repeat 18F-DCFPyL PET/CT, diagnostic CT, and/or 
magnetic resonance imaging (MRI) for evaluation of PSMA-RADS-3A lesions and 18F-
DCFPyL PET/CT, diagnostic CT, and/or 99mTc-methylene diphosphonate (MDP) whole-
body bone scan for evaluation of PSMA-RADS-3B lesions.  
In addition to PSMA-RADS Version 1.0 categorization, the maximum 
standardized uptake values (SUVmax) corrected for lean body mass for all of the lesions 
and the mean SUV (SUVmean) of blood pool (determined by a 3-cm sphere in the 
ascending aorta) were measured. The ratios of SUVmax of each lesion corrected for the 
SUVmean of blood pool (SUVmax-lesion/SUVmean-bloodpool) were calculated. 
In regards to the longitudinal follow-up of the PSMA-RADS-3A and PSMA-RADS-
3B lesions, central review was again carried out and a consensus was reached as to 
the nature of the imaging findings on the follow-up studies. Lesions that were 
determined on follow-up to be suggestive of the presence of PCa met at least one of the 
following criteria: 
① Follow-up PET/CT imaging with 18F-DCFPyL showed uptake of the radiotracer 
decreased or increased significantly, determined as an SUVmax change of more than 
30% after therapy (in analogy to the PERCIST criteria (21)) OR uptake of the 
radiotracer increased significantly during observation. This criterion was applied to both 
PSMA-RADS-3A and PSMA-RADS-3B lesions. 
② For PSMA-RADS-3A lesions, follow-up CT or MRI showed the diameters of the 
lesions either decreased or increased more than 2 mm after therapy OR the diameters 
of the lesions increased more than 2 mm during observation.   
③ For PSMA-RADS-3B lesions, the follow-up CT showed new sclerotic or osteolytic 
changes OR baseline faint, indeterminate sclerotic changes demonstrated increased 
sclerosis. 
④ For PSMA-RADS-3B lesions, the follow-up 99mTc-MDP whole body bone scan 
showed new avid uptake of radiotracer in the lesions. 
 
Statistical analysis 
Fisher’s exact test was used to compare the number of PSMA-RADS-3A and 
PSMA-RADS-3B lesions in different patient groups that were subsequently determined 
to be true positive for the presence of malignancy. Descriptive statistics were used to 
evaluate SUVmax and SUVmax-lesion/SUVmean-bloodpool in different types of lesions. P < 0.05 




Among the 110 patients, 56 patients (50.9%) were categorized as having at least 
one PSMA-RADS-3A and/or PSMA-RADS-3B lesion on 18F-DCFPyL PET/CT. However, 
34/56 (60.7%) lacked adequate imaging follow-up to definitively assess their lesions in a 
longitudinal manner. This relatively high rate of patients without adequate follow-up 
imaging may have been related to multiple factors including patients undergoing 
metastasis-directed therapy if their 18F-DCFPyL PET/CT scans showed limited sites of 
disease and achieving complete biochemical responses or seeking second opinions or 
transferring care after the results of the scans.  
The 22/56 (39.3%) remaining patients were included in the subsequent analysis. 
In regards to available follow-up imaging, 20/22 (90.9%) patients had diagnostic 
chest/abdomen/pelvis CT scans, 14/22 (63.6%) had whole body BS, 3/22 (13.6%) had 
abdomen and/or pelvis MRI, and 7/22 (31.8%) had 18F-DCFPyL PET/CT scans. Median 
follow-up time was 10 months (range 3 – 22 months). Selected demographic and 
clinical information on these patients is included in Table 1.  
 
Image Analysis 
Among the 22 patients with usable longitudinal follow-up, there were a total of 46 
lesions designated as PSMA-RADS-3A or PSMA-RADS-3B. 32/46 (69.6%) were 
categorized as PSMA-RADS-3A, which included 15 retroperitoneal lymph nodes (LNs) 
(15/32, 46.9%), 13 pelvic LNs (13/32, 40.6%), and four supraclavicular LNs (4/32, 
12.5%). All included PSMA-RADS-3A LNs measured much less than 1 cm in axial short 
axis diameter (median 0.3 cm, standard deviation 0.1 cm, range 0.2 – 0.5 cm). The 
uptake characteristics of these lesions are summarized in Table 2. 
The remaining 14/46 (30.4%) lesions were categorized as PSMA-RADS-3B. Of 
these, 12/14 (85.7%) were rib lesions, one was a scapula lesion (1/14, 7.1%), and one 
(1/14, 7.1%) was an iliac bone lesion. The scapula lesion and two of the rib lesions were 
occult on conventional imaging with no anatomic correlates. The iliac bone lesion and 
10/12 (83.3%) rib lesions demonstrated at least some measure of sclerosis, however 
the morphology (either faintly visible or punctate) was determined by the central 
reviewers to not be definitive for metastatic PCa. 
In total, 27/46 (58.7%) PSMA-RADS-3A and PSMA-RADS-3B lesions 
demonstrated changes on follow-up imaging suggesting that they were true positive for 
PCa involvement (Table 2). Among those 27 lesions, 13/27 (48.1%) met criteria ① and 
② from the materials and methods section, 9/27 (33.3%) met criterion ②, 2/27 (7.4%) 
met criterion ①, 1/27 (3.7%) met criteria ① and ③, 1/27 (3.7%) met criterion ③, and 
1/27 (3.7%) met criteria ③ and ④. 
In regards to PSMA-RADS-3A lesions, 24/32 (75.0%) demonstrated changes on 
follow-up imaging consistent with baseline disease involvement (Figure 1). In 
contradistinction, for PSMA-RADS-3B lesions, 3/14 (21.4%) lesions had findings on 
follow-up imaging appearing to confirm baseline disease involvement (Figure 2). On a 
patient level analysis, 15/22 patients (68.2%) had at least one PSMA-RADS-3A or 
PSMA-RADS-3B lesion undergo changes on follow-up imaging consistent with 
malignant involvement. In terms of number of lesions per patient, 13/22 (59.1%) 
patients had a single PSMA-RADS-3A or PSMA-RADS-3B lesion and 9/22 (40.9%) 
patients had two or more such lesions (maximum seven). 9/13 (69.2%) solitary lesions 
had findings on follow-up imaging consistent with disease involvement. For the patients 
with more than one PSMA-RADS-3A or PSMA-RADS-3B finding, 18/33 (54.5%) lesions 
in 6/9 (66.7%) patients demonstrated evidence of malignancy on follow-up imaging.  
Stratifying by the number of PSMA-RADS-4 and PSMA-RADS-5 lesions present 
in the same patient on baseline 18F-DCFPyL PET/CT indicated that PSMA-RADS-3A 
and PSMA-RADS-3B findings were more likely to evidence signs of malignancy on 
follow-up imaging if other definitively malignant lesions were present. The lesions were 
divided into three groups: group 1 (n=10) without PSMA-RADS-4 or PSMA-RADS-5 
lesions in the same patient, group 2 (n=16) with one to three PSMA-RADS-4 or PSMA-
RADS-5 lesions in the same patient, and group 3 (n=20) with more than 3 PSMA-
RADS-4 and PSMA-RADS-5 lesions in the same patient. The number of lesions 
demonstrating evidence of malignancy on follow-up imaging was 3/10 (30.0%) in group 
1, 6/16 (37.5%) in group 2 and 18/20 (90.0%) in group 3. The differences among the 
three groups reached statistical significance (P < 0.05). 
The SUVmaxs of PSMA-RADS-3A and PSMA-RADS-3B lesions were similar with 
overlapping ranges, although the median SUVmax of PSMA-RADS-3A lesions was 
higher than the corresponding median SUVmax of PSMA-RADS-3B lesions (median 
SUVmax of PSMA-RADS-3A lesions was 1.62 with a range from 0.93 to 2.32, while the 
median SUVmax of PSMA-RADS-3B lesions was 1.15 with a range from 0.85 to 1.89, 
respectively) (Table 2). In comparing those lesions that had characteristic changes of 
malignancy on follow-up imaging versus those that remained unchanged, the median 
SUVmax was actually marginally higher for the unchanged lesions, although again the 
SUVmax ranges overlapped (median SUVmax for changed lesions was 1.53 with a range 
from 1.05 to 2.32, while the median SUVmax for unchanged lesions was 1.30 with a 
range from 0.85 to 2.09, respectively) (Table 2). Additional characteristics of the lesions 
can be found in Table 2. 
The analyses based on SUVmax-lesion/SUVmean-bloodpool produced similar results, 
suggesting that the SUVmax ranges encountered for PSMA-RADS-3A and PSMA-RADS-
3B lesions are not significantly impacted by blood pool radiotracer concentration at the 
time of imaging. Median SUVmax-lesion/SUVmean-bloodpool for PSMA-RADS-3A lesions was 
1.64 with a range from 0.90 to 2.81 and for PSMA-RADS-3B lesions the median was 
1.18 with a range from 0.77 to 1.63. Again, the ranges of SUVmax-lesion/SUVmean-bloodpool 
for lesions with changes suggesting malignancy versus unchanged lesions overlapped 
(median SUVmax-lesion/SUVmean-bloodpool for changed PSMA-RADS-3A lesions was 1.65 
(range 0.90 to 2.81), median SUVmax-lesion/SUVmean-bloodpool for unchanged PSMA-RADS-
3A lesions was 1.57 (range 1.18 to 1.76), median SUVmax-lesion/SUVmean-bloodpool for 
changed PSMA-RADS-3B lesions was 1.23 (range 1.04 to 1.42) and median SUVmax-




PSMA-targeted PET has been rapidly adopted around the world for PCa imaging 
given its high sensitivity and specificity for the identification of sites of disease (8). 
However, as with any imaging modality, there are indeterminate findings that arise either 
as a result of incidental findings or because of lesion imaging characteristics that belie 
easy categorization (16). As a result, multiple systems have been proposed to add 
structure to the interpretation of PSMA-targeted PET scans (14,22,23). While these 
systems emphasize different aspects of PSMA-targeted PET scan interpretation, the 
central aspect of PSMA-RADS version 1.0 is the categorization of lesions based on the 
interpreting imaging specialist’s suspicion of the presence of PCa (14,15). This aligns 
PSMA-RADS with previously reported organ-based reporting and data systems such as 
those for breast (breast imaging reporting and data system, BI-RADS (24)) and multi-
parametric prostate MRI (prostate imaging reporting and data system, PI-RADS (25)).  
For example, BI-RADS includes a total of seven categories that overall represent 
different probabilities of imaging findings being malignant and proffer corresponding 
recommendations (e.g. BI-RADS 3 indicates the need for 6-month follow-up imaging in 
the context of a less than 2% chance of the finding being malignant, whereas BI-RADS 
4 lesions will be found to be cancer at a rate of approximately 30% and BI-RADS 5 
lesions are almost certainly cancer with a positive predictive value of about 97% (24)). 
Knowledge of the BI-RADS categories is useful for both radiologists and clinicians for 
communication and guidance of patient management (26).  
The potential adoption of PSMA-RADS is contingent upon a similar utility for 
guiding clinical decision-making. On a global level, nearly 60% of indeterminate lesions 
on PSMA-targeted 18F-DCFPyL PET/CT were found to have changes on follow-up 
imaging compatible with disease involvement, with 75.0% of PSMA-RADS-3A lymph 
node lesions and 21.4% of PSMA-RADS-3B bone lesions meeting our pre-specified 
criteria for harboring PCa. The presence of more definitive sites of PCa (i.e. PSMA-
RADS-4 and PSMA-RADS-5 lesions) increased the likelihood of PSMA-RADS-3A and 
PSMA-RADS-3B findings having follow-up imaging findings consistent with the 
presence of PCa. 
These findings bear out that PSMA-RADS-3A and PSMA-RADS-3B are truly 
indeterminate lesions. Thus, depending on the clinical context, image-guided biopsy or 
follow-up imaging are required to determine the likelihood of malignancy. In particular, 
follow-up imaging may be of particular value in isolated PSMA-RADS-3A lesions when 
there are no other findings on the scan. PSMA-RADS-3B lesions warrant careful 
consideration as only a minority of such findings will have characteristic changes of PCa 
involvement on follow-up imaging. If patients are considered for salvage or focal 
therapies as opposed to systemic therapy, it will be necessary for clinicians to weigh the 
potential cost and toxicities associated with those therapies against the likelihood of 
PSMA-RADS-3A and PSMA-RADS-3B lesions representing true sites of disease. 
 The most significant limitations to the current study are its retrospective nature 
and that lesions were not correlated to histopathology. As would be expected for 
indeterminate lesions on PSMA-targeted PET imaging, the findings were often small 
and would be difficult to reliably target with conventional imaging guidance for biopsy. 
Therefore, histopathology is a difficult gold standard to apply to this study and follow-up 
imaging findings may represent a more practical approach to determining the nature of 
lesions (2). Further, because of the small size and/or lack of conspicuity of many PSMA-
RADS-3A and PSMA-RADS-3B lesions on conventional imaging, we were unable to 
apply commonly used response/progression criteria such as RECIST 1.1 (27) to 
objectively categorize findings on follow-up. We also acknowledge that with the often 
indolent nature of PCa, some lesions which remained unchanged on follow-up imaging 
could still represent sites of PCa and that our percentages of PSMA-RADS-3A and 
PSMA-RADS-3B lesions that we considered consistent with PCa involvement may be 
underestimated. Prospective longitudinal follow-up of a larger number of indeterminate 
lesions from PSMA-targeted PET scans will be critical to address these limitations.  
 
CONCLUSION 
In this study of longitudinal follow-up of lesions with indeterminate levels of 
uptake on PSMA-targeted PET, a significant majority (75.0%) of PSMA-RADS-3A 
lesions demonstrated changes on subsequent imaging compatible with the presence of 
PCa. However, only a minority (21.4%) of PSMA-RADS-3B indeterminate bone lesions 
showed changes on follow-up imaging suggestive of underlying PCa. These findings 
confirm the necessity for a category in the PSMA-RADS grading system for 
indeterminate lesions.  
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Tables and Table Legends 
Table 1. Clinical and demographic data at the time of baseline 18F-DCFPyL PET/CT 










Prior PCa Therapy PCa Therapy After 
Baseline 18F-DCFPyL 
PET/CT 
1 66 4.6 Prostatectomy Salvage Radiation, ADT 
2 69 7.8 Prostatectomy Salvage Radiation, SBRT, ADT 





4 66 6.48 
Prostatectomy, Salvage 
Radiation, ADT, SBRT, 
Provenge, 177Lu-PSMA 
Taxotere 





6 63 12 Prostatectomy, ADT ABRT, Provenge, Enzalutamide 
7 66 0.4 Prostatectomy, Salvage Radiation, ADT None 
8 65 0.5 Taxotere, ADT, SBRT, Provenge 
Provenge, SBRT, 177Lu-
PSMA 
9 61 0.3 Prostatectomy Salvage Radiation 
10 65 37.8 None EBRT, ADT 
11 71 10.8 None Prostatectomy 
12 63 2.2 Prostatectomy, ADT ADT 
13 59 5.8 Prostatectomy, Salvage Radiation, ADT SBRT 






15 53 23.3 None Taxotere, ADT 






17 69 1.4 Prostatectomy, Salvage Radiation ADT 
18 50 0.7 Prostatectomy Taxotere, ADT 
19 64 70.4 None Taxotere, ADT 
20 54 21.4 None Prostatectomy, Abiraterone, ADT 






22 63 9.7 None ADT 
*Abbreviations: ADT = androgen deprivation therapy; SBRT = stereotactic body 
radiation therapy; EBRT = external beam radiation therapy 
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Figure 1. (A) Axial attenuation correction CT, (B) axial 18F-DCFPyL PET, and (C) axial 
18F-DCFPyL PET/CT from a patient with a 3-mm short axis, pre-aortic, retroperitoneal 
lymph node with faint radiotracer uptake slightly higher than blood pool (red 
arrowheads). This was determined by central review to be a PSMA-RADS-3A lesion. (D) 
Follow-up axial attenuation correction CT, (E) axial 18F-DCFPyL PET, and (F) axial 18F-
DCFPyL PET/CT six months later after multiple treatment modalities including androgen 
deprivation therapy. The node had definitively decreased in size and lacked any 
discernable uptake on the follow-up scan (red arrowheads), most compatible with PCa 
involvement. 
Figure 2. (A) Axial attenuation correction CT, (B) axial 18F-DCFPyL PET, and (C) axial 
18F-DCFPyL PET/CT from a patient with faint uptake in the inferior right scapula (red 
arrowheads). This was determined on central review to represent a PSMA-RADS-3B 
lesion without a visible anatomic correlate. (D) Follow-up axial attenuation correction 
CT, (E) axial 18F-DCFPyL PET, and (F) axial 18F-DCFPyL PET/CT 10 months later show 
markedly increased radiotracer uptake and new sclerosis in the inferior right scapula 
(red arrowheads), most consistent with a PCa bone metastasis. The patient had started 
on taxotere chemotherapy but had a rising prostate specific antigen level at the time of 
follow-up imaging, consistent with progressive systemic disease.  
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